Endoscopic detection of an early manifestation of EBV-related post-transplant lymphoproliferative disorder in a transplanted colon




Fig. 1 a Colonoscopic view of transplanted colon 26 days after transplantation, showing erythema and easily bleeding epithelia.

Intestinal transplantation in children requires close follow-up, including endoscopic monitoring of the transplanted organ via the temporary stoma and/or anus with biopsies taken and reviewed. We present a case of post-transplant lymphoproliferative disorder (PTLD) diagnosed less than 1 month after transplantation. PTLD is a common life-threatening complication after intestinal transplantation, occurring in 13.5% of pediatric cases, and is mostly related to Epstein-Barr virus (EBV) [1,2].


A 5-year-old boy presented with intestinal failure secondary to microvillus inclusion disease. He received an isolated intestinal allograft combined with a proximal colonic allograft. To monitor for rejection and inflammation, colonoscopy and endoscopic review through the stoma were performed twice a week in the first 2 weeks and once a week after that.

Lesions were detected 26 days after transplantation (Fig. 1 a).

Microscopy of the transplanted colon and the host colon revealed a polymorphous lymphocytic infiltrate in the lamina propria, non-tumor-forming (Fig. 1 b). This



b Biopsy specimen of donor colon, showing a polymorphous lymphocytic infiltrate in the lamina propria, non-tumor-forming (H&E, × 100).



c In situ hybridization for EBV-related small RNAs (EBERs) showing positive B cells surrounding negative crypts containing T cells.

PTLD consisted of CD20- and CD79a-positive B cells that harbored EBV-related small RNAs (EBERs) as determined by in situ hybridization (**> Fig. 1c**).

The tacrolimus dose was lowered. However, 6 days later endoscopic review showed that the lesions had grown and were also present in the donor proximal ileum (Fig. 2a).

Reduction of immunosuppressive therapy and administration of a monoclonal anti-

body directed against the B-cell receptor CD20 (rituximab) [3,4] induced immediate regression of the lymphomas and complete remission of the disorder within 3 months after the first dose.

Six months after transplantation there was an acute episode of therapy-resistant rejection, which needed graft exploration and excision. The patient has been relisted for combined intestinal and liver transplantation. He is awaiting the retrans-



Fig. 2 a Colonoscopic view of transplanted colon 32 days after transplantation, showing tumor forming and white ulceration.

plantation at home in a clinically stable condition. This case represents the earliest presentation of intestinal PTLD found during routine endoscopic surveillance.

Acknowledgements


▼

We would like to thank all members of the intestinal transplant team of the University Medical Center Groningen for their joint efforts to care for children with intestinal failure.


Endoscopy_UCTN_Code_CCL_1AD_2AJ

M. W. van Ginkel¹, A. Diepstra², G. Dijkstra³, V. B. Nieuwenhuijs⁴, Z. J. de Langen⁴, E. H. H. M. Rings¹

- Division of Pediatric Gastroenterology, Department of Pediatrics, Beatrix Children's Hospital, University Medical Center Groningen, Groningen, The Netherlands
- ² Department of Pathology and Medical Biology. University Medical Center Groningen, Groningen, The Netherlands
- Department of Gastroenterology, University Medical Center Groningen, Groningen, The Netherlands
- Department of Surgery, University Medical Center Groningen, Groningen, The Netherlands



b Biopsy specimen of donor colon, showing ulceration of the colon epithelia with destruction of the crypts (H&E, × 100).



c In situ hybridization for EBERs showing positive B cells in the lamina propria, tumor forming.

References

- 1 Intestinal Transplant Registry May 31, 2003. http://www.intestinaltransplant.org/; Publication date: 2003
- 2 *Tanner JE, Alfeiri C.* The Epstein-Barr virus and post transplant lymphoproliferative disease: interplay of immunosuppression, EBV, and the immune system in disease pathogenesis. Transpl Infect Dis 2001; 3: 20–69
- 3 Choquet S, Leblond V, Herbrecht R et al. Efficacy and safety of rituximab in B-cell posttransplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study. Blood 2006; 107: 3053 – 3057
- 4 *Svoboda J, Kotloff R, Tsai DE.* Management of patients with post-transplant lymphoproliferative disorder: the role of rituximab. Transpl Int 2006; 19: 259 269

Bibliography

DOI 10.1055/s-0029-1243865 Endoscopy 2010; 42: E101 – E102 © Georg Thieme Verlag KG Stuttgart · New York · ISSN 0013-726X

Corresponding author

E. H. H. M. Rings, MD, PhD

Beatrix Children's Hospital University Medical Center Groningen University of Groningen P.O. Box 30.001 9700 RB Groningen The Netherlands Fax: +31-50-3614235 e.h.h.m.rings@bkk.umcg.nl